Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia.

Whitwell JL, Martin PR, Duffy JR, Clark HM, Machulda MM, Schwarz CG, Weigand SD, Sintini I, Senjem ML, Ertekin-Taner N, Botha H, Utianski RL, Graff-Radford J, Jones DT, Boeve BF, Knopman DS, Petersen RC, Jack CR Jr, Lowe VJ, Josephs KA.

Neurology. 2019 Feb 12;92(7):e710-e722. doi: 10.1212/WNL.0000000000006913. Epub 2019 Jan 11.

PMID:
30635491
2.

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.

Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O'Neil JP, Janabi M, Baker S, Lee SE, Perry DC, Bajorek L, Karydas A, Spina S, Grinberg LT, Seeley WW, Ramos EM, Coppola G, Gorno-Tempini ML, Miller BL, Rosen HJ, Jagust W, Boxer AL, Rabinovici GD.

Alzheimers Res Ther. 2019 Jan 31;11(1):13. doi: 10.1186/s13195-019-0470-7.

3.

Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM.

JAMA Neurol. 2016 Sep 1;73(9):1070-7. doi: 10.1001/jamaneurol.2016.2078.

4.

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.

JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216.

5.

[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.

Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, Lee YB, Park KH, Heo JH, Yoon CW, Kang JM, Cho J, Okamura N, Furumoto S, Yanai K, Na DL, Ido T, Villemagne VL, Noh Y.

Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):62-69. doi: 10.1097/WAD.0000000000000216.

PMID:
29028649
6.

[18 F]AV-1451 tau-PET and primary progressive aphasia.

Josephs KA, Martin PR, Botha H, Schwarz CG, Duffy JR, Clark HM, Machulda MM, Graff-Radford J, Weigand SD, Senjem ML, Utianski RL, Drubach DA, Boeve BF, Jones DT, Knopman DS, Petersen RC, Jack CR Jr, Lowe VJ, Whitwell JL.

Ann Neurol. 2018 Mar;83(3):599-611. doi: 10.1002/ana.25183. Epub 2018 Mar 13.

7.

[18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, Arnold R, Allinson KSJ, Coles JP, Aigbirhio FI, Patterson K, O'Brien JT, Rowe JB.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1032-1037. doi: 10.1136/jnnp-2017-316402. Epub 2017 Sep 14.

8.

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.

Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA; 18F-AV-1451-A05 investigators.

Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

9.

18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia.

Cho H, Kim HJ, Choi JY, Ryu YH, Lee MS, Na DL, Seo SW, Lyoo CH.

Neurobiol Aging. 2019 Mar;75:187-197. doi: 10.1016/j.neurobiolaging.2018.11.017. Epub 2018 Nov 23.

PMID:
30594046
10.

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

Winer JR, Maass A, Pressman P, Stiver J, Schonhaut DR, Baker SL, Kramer J, Rabinovici GD, Jagust WJ.

JAMA Neurol. 2018 Feb 1;75(2):227-235. doi: 10.1001/jamaneurol.2017.3713.

11.

Flortaucipir tau PET imaging in semantic variant primary progressive aphasia.

Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, Vasdev N, Johnson KA, Dickerson BC.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1024-1031. doi: 10.1136/jnnp-2017-316409. Epub 2017 Oct 6.

12.

18F-Flortaucipir in TDP-43 associated frontotemporal dementia.

Smith R, Santillo AF, Waldö ML, Strandberg O, Berron D, Vestberg S, van Westen D, van Swieten J, Honer M, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6082. doi: 10.1038/s41598-019-42625-9.

13.

[18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review.

Kobayashi R, Hayashi H, Kawakatsu S, Ishiki A, Okamura N, Arai H, Otani K.

BMC Neurol. 2018 Aug 8;18(1):109. doi: 10.1186/s12883-018-1115-3. Review.

14.

Amyloid and tau PET demonstrate region-specific associations in normal older people.

Lockhart SN, Schöll M, Baker SL, Ayakta N, Swinnerton KN, Bell RK, Mellinger TJ, Shah VD, O'Neil JP, Janabi M, Jagust WJ.

Neuroimage. 2017 Apr 15;150:191-199. doi: 10.1016/j.neuroimage.2017.02.051. Epub 2017 Feb 21.

15.

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.

Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JF, Cosio D, Schultz A, Lapoint M, Guzman-Velez E, Miller JB, Kim LA, Chen K, Tariot PN, Lopera F, Reiman EM, Johnson KA.

JAMA Neurol. 2018 May 1;75(5):548-556. doi: 10.1001/jamaneurol.2017.4907.

16.

AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.

Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG, Spychalla AJ, Gunter JL, Fields JA, Graff-Radford J, Ferman TJ, Jones DT, Murray ME, Knopman DS, Jack CR Jr, Petersen RC.

Ann Neurol. 2017 Jan;81(1):58-67. doi: 10.1002/ana.24825. Epub 2016 Dec 19.

17.

Dual-phase 18F-florbetapir positron emission tomography in patients with primary progressive aphasia, Alzheimer's disease, and healthy controls: A preliminary study.

Kuo HC, Hsiao IT, Hsieh CJ, Huang CY, Huang KL, Wai YY, Chuang WL, Kung MP, Chu YC, Yen TC, Lin KJ, Huang CC.

J Formos Med Assoc. 2017 Dec;116(12):964-972. doi: 10.1016/j.jfma.2017.03.003. Epub 2017 Apr 20.

18.

Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2013 Mar;136(Pt 3):844-58. doi: 10.1093/brain/aws327. Epub 2013 Jan 28.

19.

Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.

Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1304-14. doi: 10.1007/s00259-016-3359-8. Epub 2016 Mar 22.

PMID:
27003417
20.

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue.

Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T.

Ann Neurol. 2015 Nov;78(5):787-800. doi: 10.1002/ana.24517. Epub 2015 Sep 25.

Supplemental Content

Support Center